PML: Not all about tumor suppression

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Martin Martin, Natalia ^a   Sutherland, James D ^a   Carracedo, Arkaitz ^a,b,c  

^a CIC BIOGUNE   (Spain)

^b BASQUE FOUNDATION FOR SCIENCE   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; FATTY ACID OXIDATION; HUMAN; MYELOID PROGENITOR CELL; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PROCESSING; TUMOR MICROENVIRONMENT;

EID: 84891092810     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00200     Document Type: Article

References (58)

1. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 66:663-74. doi:10.1016/0092-8674(91)90112-C
2. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science (1991) 254:1371-4. doi:10.1126/science.1720570
3. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 6:1285-92.
4. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 66:675-84. doi:10.1016/0092-8674(91)90113-D
5. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer (2001) 1:181-93. doi:10.1038/35106036
6. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 96:269-79. doi:10.1093/jnci/djh043
7. Lang M, Jegou T, Chung I, Richter K, Münch S, Udvarhelyi A, et al. Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci (2010) 123:392-400. doi:10.1242/jcs.053496
8. Shen TH, Lin H-K, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms of PML-nuclear body formation. Mol Cell (2006) 24:331-9. doi:10.1016/j.molcel.2006.09.013
9. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene (1999) 18:7941-7. doi:10.1038/sj.onc.1203367
10. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 8:1006-16. doi:10.1038/nrm2277
11. Bøe SO, Haave M, Jul-Larsen A, Grudic A, Bjerkvig R, Lønning PE. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. J Cell Sci (2006) 119:3284-95. doi:10.1242/jcs.03068
12. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays (2004) 26:963-77. doi:10.1002/bies.20089
13. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de Thé H. PML nuclear bodies and apoptosis. Oncogene (2004) 23:2819-24. doi:10.1038/sj.onc.1207533
14. Bernardi R, Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene (2003) 22:9048-57. doi:10.1038/sj.onc.1207106
15. Giorgi C, Ito K, Lin H-K, Santangelo C, Wieckowski MR, Lebiedzinska M, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 330:1247-51. doi:10.1126/science.1189157
16. Yang S, Jeong JH, Brown AL, Lee CH, Pandolfi PP, Chung JH, et al. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem (2006) 281:26645-54. doi:10.1074/jbc.M601356200
17. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell (2010) 18:258-67. doi:10.1016/j.ccr.2010.08.008
18. Yang Q, Liao L, Deng X, Chen R, Gray NS, Yates JR III, et al. BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene (2013) 32:3156-64. doi:10.1038/onc.2012.332
19. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 442:779-85. doi:10.1038/nature05029
20. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 441:523-7. doi:10.1038/nature04809
21. Gurrieri C, Nafa K, Merghoub T, Bernardi R, Capodieci P, Biondi A, et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood (2004) 103:2358-62. doi:10.1182/blood-2003-07-2200
22. Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature (1998) 396:373-6. doi:10.1038/24628
23. Salomoni P, Bellodi C. New insights into the cytoplasmic function of PML. Histol Histopathol (2007) 22:937-46.
24. Bellodi C, Kindle K, Bernassola F, Dinsdale D, Cossarizza A, Melino G, et al. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem (2006) 281:14465-73. doi:10.1074/jbc.M600457200
25. Bellodi C, Kindle K, Bernassola F, Cossarizza A, Dinsdale D, Melino G, et al. A cytoplasmic PML mutant inhibits p53 function. Cell Cycle (2006) 5:2688-92. doi:10.4161/cc.5.22.3504
26. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 11:871-6.
27. Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, Saïb A, et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene (1995) 11:2565-73.
28. Kim TK, Lee JS, Oh SY, Jin X, Choi YJ, Lee TH, et al. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res (2007) 67:11133-40. doi:10.1158/0008-5472.CAN-07-1342
29. Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, et al. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem (2007) 282:5633-40. doi:10.1074/jbc.M607825200
30. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 14:2015-27.
31. de StanchinaE, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 13:523-35. doi:10.1016/S1097-2765(04)00062-0
32. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 406:207-10. doi:10.1038/35018127
33. Jiang WQ, Ringertz N. Altered distribution of the promyelocytic leukemia-associated protein is associated with cellular senescence. Cell Growth Differ (1997) 8:513-22.
34. Scaglioni PP, Rabellino A, Yung TM, Bernardi R, Choi S, Konstantinidou G, et al. Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence. EMBO Mol Med (2012) 4:594-602. doi:10.1002/emmm.201200233
35. Yoshida H, Ichikawa H, Tagata Y, Katsumoto T, Ohnishi K, Akao Y, et al. PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation. Mol Cell Biol (2007) 27:5819-34. doi:10.1128/MCB.02422-06
36. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene (2001) 20:7223-33. doi:10.1038/sj.onc.1204765
37. Cheng X, Kao H-Y. Post-translational modifications of PML: consequences and implications. Front Oncol (2012) 2:210. doi:10.3389/fonc.2012.00210
38. Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T. Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem (2008) 283:24420-5. doi:10.1074/jbc.M802217200
39. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 453:1072-8. doi:10.1038/nature07016
40. Carracedo A, Weiss D, Leliaert AK, Bhasin M, de Boer VC, Laurent G, et al. A metabolic prosurvival role for PML in breast cancer. J Clin Invest (2012) 122:3088-100. doi:10.1172/JCI62129
41. Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, et al. A PML-PPAR-d pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 18:1350-8. doi:10.1038/nm.2882
42. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 13:227-32. doi:10.1038/nrc3483
43. Massagué J. TGFbeta in Cancer. Cell (2008) 134:215-30. doi:10.1016/j.cell.2008.07.001
44. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res (2005) 11:937s-43.
45. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-ß in cancer. J Pathol (2011) 223:205-18. doi:10.1002/path.2785
46. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet (2012) 13:654-66. doi:10.1038/nrg3272
47. Becam I, Fiuza U-M, Arias AM, Milán M. A role of receptor Notch in ligand cis-inhibition in Drosophila. Curr Biol (2010) 20:554-60. doi:10.1016/j.cub.2010.01.058
48. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene (2008) 27:5124-31. doi:10.1038/onc.2008.226
49. Shih I-M, Wang T-L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res (2007) 67:1879-82. doi:10.1158/0008-5472.CAN-06-3958
50. Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med (2013) 19:320-7. doi:10.1016/j.molmed.2013.03.003
51. Yu L, Wang L, Chen S. Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim Biophys Acta (2013) 1835:144-54. doi:10.1016/j.bbcan.2012.10.006
52. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 27:218-24. doi:10.1038/sj.onc.1210904
53. Louderbough JMV, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res (2011) 9:1573-86. doi:10.1158/1541-7786.MCR-11-0156
54. Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer (2011) 2:648-62. doi:10.1177/1947601911417862
55. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin's dark side: possible role in tumor progression. Biochim Biophys Acta (2012) 1826:23-31. doi:10.1016/j.bbcan.2012.03.002
56. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 10:547-55. doi:10.1038/ncb1717
57. Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H. Curing APL through PML/RARA degradation by As2O3. Trends Mol Med (2012) 18:36-42. doi:10.1016/j.molmed.2011.10.001
58. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol (2008) 10:538-46. doi:10.1038/ncb1716